Nanjing China-Australia Institute of Translational Medicine Co. Ltd. has disclosed baculoviral IAP repeat-containing protein 3 (BIRC3; IAP1; cIAP2), baculoviral IAP repeat-containing protein 2 (BIRC2; IAP2; cIAP1) and E3 ubiquitin-protein ligase XIAP (XIAP; BIRC4; IAP3) inhibitors reported to be useful for the treatment of cancer.
At the ESHG meeting in Berlin, a novel causative gene for Perrault syndrome was presented by a researcher from the University of Manchester. Perrault syndrome is a rare autosomal recessive disease characterized by sensorineural hearing loss and primary ovarian insufficiency.
Researchers from the University of Science and Technology of China (USTC) reported data from a study that aimed to assess the effects of the highly selective telomerase inhibitor, BIBR-1532, on immune activation induced by radiotherapy (RT).
Odimma Therapeutics SAS has developed ODI-2001, a new biological from the combination of neoantigen-expressing DNA vector, an anti-CTLA-4 antibody and an attenuated poxvirus with the aim of increasing the immune response against tumors.
A preclinical trial in mice and ferrets of an experimental mRNA vaccine against the H5 highly pathogenic avian influenza (HPAI) virus generated neutralizing antibodies and prevented severe illness and mortality of the animals.
Ventyx Biosciences Inc. has released promising preclinical data for its CNS-penetrant NLRP3 inhibitor VTX-3232 in murine diet-induced obesity (DIO) models.
Researchers from Septerna Inc. presented the discovery and preclinical characterization of novel parathyroid hormone PTH1 receptor (PTH1R) agonists being developed as a new treatment option against hypoparathyroidism.
The ongoing European Association for the Study of the Liver 2024 congress in Milan opened yesterday with several presentations on cell plasticity and its role in liver function and regeneration in chronic liver disease situations.
RSS
